Seattle Genetics, Inc. has recieved a license fee in an undisclosed amount from Genencor International, Inc. under the terms of a strategic alliance formed by the two companies in January 2002. The collaboration involves the joint discovery and development of a class of cancer therapeutics based on tumor-targeted enzymes that activate prodrugs. At the time Read more about Seattle Genetics Receives License Fee From Genencor[…]
Bayer Corporation, Diagnostics Division and Visible Genetics Inc. (VGI) have signed a definitive agreement providing for Bayer Diagnostics to acquire VGI in a cash deal valued at $61.4 million, significantly expanding Bayer’s position in the growing Nucleic Acid Diagnostic (NAD) segment of the Professional Laboratory market. Bayer will purchase, for cash consideration, VGI’s outstanding common Read more about Bayer Diagnostics To Acquire Visible Genetics[…]
Isis Pharmaceuticals and Hybridon have announced the cancellation of the remaining financial obligations related to their Collaboration and License Agreement that the companies completed in May 2001. Under the original agreement, Hybridon owed Isis an additional 4 million shares of Hybridon common stock, payable immediately. Isis owed Hybridon $4.5 million in cash or stock, due Read more about Isis And Hybridon Cancel Reciprocal Financial Obligations[…]
Anadys Pharmaceuticals, Inc. and Sequoia Sciences, Inc. have entered into a drug discovery collaboration to identify novel anti-infectives. This partnership will harness Sequoia’s unique library of compounds isolated from natural products using the fully integrated drug discovery capabilities of Anadys. Under the terms of the agreement, Anadys will deploy its proprietary screening technologies uHTS-ATLAS and Read more about Anadys And Sequoia Sciences Announce Drug Discovery Collaboration[…]
Epimmune Inc. has entered into an evaluation and license option agreement with Immuno-Designed Molecules, S.A. (IDM) for certain cancer antigens for use in IDM’s ex vivo cancer therapy program. Under the terms of the agreement, IDM will have 120 days from the date of the option agreement to evaluate the epitopes and exercise its option Read more about Epimmune And Immuno-designed Molecules Agree License Option[…]
Transgenomic Inc. and non-profit organization PXE International have entered into a collaboration to develop a diagnostic test for the genetic condition, pseudoxanthoma elasticum, commonly known as PXE. The intent is to develop a test based on Transgenomic’s WAVE System and make it available to laboratories around the world. PXE, which affects an estimated one in Read more about Transgenomic Signs Collaboration Agreement With PXE[…]
Discovery Laboratories, Inc. and CollaGenex Pharmaceuticals, Inc. announced a research collaboration to evaluate the combination of their platform technologies for the development of novel respiratory disease therapeutics. The two companies will collaborate on the preclinical evaluation of an aerosolized formulation of Discovery’s humanized lung surfactants combined with CollaGenex‘s IMPACS (Inhibitors of Multiple Proteases and CytokineS) Read more about Discovery And Collagenex Collaborate[…]
International Therapeutics, Inc. has entered into a Collaborative Research Agreement with City of Hope National Medical Center and Beckman Research Institute (Duarte, CA), to evaluate and characterize novel small interfering RNA (siRNA) molecules against HIV. siRNA are short anti-sense (mirror image) oligonucleotides that exert their effect by causing messenger RNA degradation, and in turn, inhibit Read more about International Therapeutics Announces Collaboration With City Of Hope[…]
Discovery Partners International, Inc. has entered into an agreement with Glaxo SmithKline for the delivery of a next generation IRORI(TM) Combinatorial Chemistry Synthesis Platform. Financial terms of the arrangements were not released. Over the next twelve months, Discovery Partners will deliver the first two next generation X-Kan(TM) Chemistry Synthesis Systems for use in GSK sites Read more about Discovery Partners Announces Agreement With GSK[…]
Theratechnologies has signed another license agreement with Bioartificial Gel Technologies (B.A.G.Tech), extending the license granted in 1999 relating to its extraction process and the applications of its platelet-derived growth factor cocktail. The license agreement announced today covers their in vivo use for therapeutic purposes in the areas of tissue engineering and wound healing. “We are Read more about Theratechnologies Signs Further License Agreement With B.A.G.Tech[…]